A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

N/AActive Not RecruitingNCT06549608

Bristol-Myers Squibb685 enrolled

Overview

This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.

Study Type

OBSERVATIONAL

Enrollment

685

Conditions

Hypertrophic Cardiomyopathy

Interventions

MavacamtenDRUG

As per product label

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants ≥18 years of age. * Participants who have initiated mavacamten as part of routine clinical care, through the BMS-sponsored CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. * Participants who consented to the use of their de-identified data, generated from information collected in the course of the program. Exclusion Criteria: • There are no exclusion criteria.

Locations (1)

St. Paul's Hospital

Vancouver, British Columbia, Canada

Outcomes

Primary Outcomes

Participant demographics

Time frame: Baseline

Participant clinical characteristics

Time frame: Baseline

Secondary Outcomes

Dose regimen of mavacamten treatment

Time frame: Every 3-months up to 14 months

Titration patterns of mavacamten treatment

Time frame: Up to 14 months

Mavacamten treatment duration

Time frame: Up to 14 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.